Innate Pharma S.A. announced a conference call and webcast to discuss its full‑year 2025 financial results, scheduled for Thursday, March 26, 2026.
The company’s 2024 results showed a sharp decline in revenue to €20.1 million, down from €61.6 million in 2023, and a widening loss of €49.5 million versus €7.6 million in 2023. Cash on hand was €91.1 million at the end of 2024 and €56.4 million at the end of September 2025, giving the company a runway that extends to the end of Q3 2026.
Analysts had projected a Q4 2025 EPS of ($0.3492) and revenue of $1.96 million, while Q3 2025 revenue was forecast at $2.20 million. These estimates set a benchmark against which the upcoming results will be measured.
The decline in 2024 revenue was largely driven by a reduction in collaboration and licensing agreements, and the company is pursuing a strategic pivot toward high‑value clinical assets such as IPH4502, lacutamab, and monalizumab. A 30 % headcount reduction is underway, and the FDA’s Breakthrough Therapy designation for lacutamab in Sézary syndrome provides a potential acceleration pathway for that asset.
Continuing‑operations revenue fell 67.4 % in 2024 compared with 2023, underscoring the impact of the company’s shift away from legacy licensing income toward its pipeline portfolio.
Management highlighted the importance of the company’s cash position and extended runway as a foundation for pursuing strategic priorities, while emphasizing a focus on innovation and partnership development to support the pipeline and reduce operating costs.
The company’s stock had been trending downward in early March 2026, a reflection of investor concern over the 2024 financial performance and the ongoing restructuring. The earnings call is expected to provide clarity on the company’s financial trajectory and the progress of its key pipeline assets.
The call will offer investors a detailed view of Innate Pharma’s financial health, guidance for 2025, and updates on the development of IPH4502, lacutamab, and monalizumab, helping to assess the company’s future prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.